|drug3025||Schirmer Test I Wiki||0.71|
|drug1300||Favipiravir Placebo Wiki||0.50|
|D015817||Eye Infections NIH||0.71|
There are 2 clinical trials
The aim of this study is to assess the virus RNA, and miRNA levels related to viral infection, and inflammatory response in tears of hospitalized patients with a diagnosis of COVID-19 with and without conjunctivitis and to correlate them with clinical condition. Tears will be collected by using Schirmer Test I, a non invasive painless test which can be performed at the patient's bed. Tears will be collected on the graduated paper strips pulling the lower lid gently downward for 5 minutes. Following, the strip will be placed in a 2.0 mL Eppendorf tube and stored at -80◦C (or - 20°C)
Description: - to asses virus RNA and miRNA levels in tearsMeasure: virus molecular analysis Time: 2 weeks
Description: - to asses inflammatory response moleculesMeasure: host molecular analysis Time: 2 weeks
Description: To analyze the prevalence of conjunctivitis in patients with a diagnosis of COVID-19 and the assessment of the predictive value of conjunctivitis in the development of the COVID-19 disease (or in developing respiratory distress forms-ARDS).Measure: Epidemiologic data Time: 2 weeks
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified, highly contagious RNA virus causing respiratory infectious disease, Coronavirus Disease 2019 (COVID-19). Conjunctivitis has been reported as a rare finding of the disease, and preliminary studies showed that the virus RNA could be detected in ocular secretions using polymerase chain reaction (PCR) assays when conjunctivitis present. This study aims to estimate the proportion of SARS-CoV-2 associated conjunctivitis among patients with suspected viral conjunctivitis presented to the ophthalmology clinics of Wilmer Eye Institute during the COVID-19 pandemic. The investigators also aim to identify whether SARS-CoV-2 associated conjunctivitis is an isolated finding or an early sign of COVID-19.
Description: Number of conjunctival samples with positive PCR divided by the total number of conjunctival samplesMeasure: Proportion of conjunctival samples tested positive for SARS-CoV-2 Time: 1 year
Description: Number of nasal samples with positive PCR divided by the number of conjunctival samples with positive PCRMeasure: Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples Time: 1 year
Description: Number of nasopharyngeal samples with positive PCR divided by the number of conjunctival samples with positive PCRMeasure: Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples Time: 1 year
Description: Number of patients developed COVID-19 divided by the number of the study populationMeasure: Rate of development of COVID-19 in the study patient population Time: 1 year
Description: Number of conjunctival samples with positive PCR divided by the number of patients developed COVID-19Measure: Positive conjunctival sample rate in patient developed COVID-19 Time: 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports